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Abstract: Primary cutaneous lymphomas are the second most common site of extranodal non-Hodgkin lymphoma. 
A speciﬁ  cally type named extranodal marginal zone B-cell lymphomas are indolent low-grade neoplasma.
We report a case of a 42-year-old white man with multiple subcutaneous tumors located on the trunk and neck. The 
histopathological exam showed a non-epidermotropic, dense lymphocytic inﬁ  ltrate. Histologic, immunohistochemical and 
cytologenetic analysis diagnosed primary cutaneous B-cell lymphoma MALT type. Investigation for other extranodal MALT 
lymphoma gastrointestinal tract, lung, salivary and thyroid glands was negative. The patient refused radiotherapy, but he 
accepted every 6 months close follow-up. Over a seven years period, we noticed a progressively disappearance of the skin 
lesions.
The necessity of aggressive treatment of this disease with excellent prognosis is discussed.
The treatment necessity of primary cutaneous B-cell lymphoma MALT type is discussed.
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Introduction
Extranodal marginal zone B-cell lymphomas [EMZL, mucosa-asociated lymphoid tissue (MALT) 
lymphomas] are typically indolent low-grade neoplasma that can develop in a variety of sites from 
reactive inﬁ  ltrates associated with chronic infections or autoimmune processes.
Primary cutaneous B-cell lymphomas (PCBCLs) comprise approximately 20% of cutaneous 
lymphomas (Zackheim et al. 2000). The low-grade subtype is separated in marginal zone (MZL) and 
follicle center lymphomas according to the recent World Health Organization—European Organization 
for Research and Treatment of Cancer classiﬁ  cation, with distinct histologic and immuohistochemical 
proﬁ  les (Burg et al. 2005).
In a recent study (de la Fourchardin et al. 2005) MZL showed to have a good prognosis, although 
transformation can occur, needing more aggressive treatment.
We report a case that cured without any therapeutical intervention.
Case Report
A 42-year-old man presented with multiple skin lesions on the neck, trunk and upper arms, consisting 
in inﬁ  ltrated deep red violaceus nodules measuring 1–1,5 cm (Fig. 1). The lesions had appeared 8 months 
before. The patient is a hepatitis C carrier, without any biochemical sign of chronic active hepatitis. 
Histopathological examination showed a diffuse inﬁ  ltrate sparing the epidermis (Fig. 2). The central 
area inﬁ  ltrate contains mainly small CD20+ (Fig. 3) and CD45RA+ B cells. We used molecular analysis 
for detecting if there existed clonal proliferation of lymphoid cells and it had showed to be negative. 
Staining for Bcl-6, CD10 (Fig. 4), CD21 and CD45RA were positive. A small number of follicular and 
extrafollicular B cells showed expression of Bcl-2 protein. The t(14; 18) translocation with RTQ-PCR 
(Taqman) method was not found. Polymerase chain reaction (PCR) for Borrelia burgdorfer ﬂ  agellin 
gene was negative in formalin-ﬁ  xed parafﬁ  n-embedded tisuue of skin biopsy. Investigation for other 
nodal and extranodal MALT lymphoma was negative. Laboratory tests, including Borrelia burgdorferi 
serology and Helicobacter pylori, were all normal, apart from conﬁ  rming the previously diagnosed 
hepatitis C. Other investigations including CT scan of the chest, abdomen and pelvis, showed no 154
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abnormalities. The bone marrow exam was 
negative. These ﬁ  ndings conﬁ  rmed the clinical and 
histopathological diagnosis of primary marginal 
zone cutaneous B-cell lymphoma.
In order to perform further control of the patient 
liver’s function, he was advised to consult a gas-
trenterologist. Liver function and the general 
check-up of all gastrenterologist system were 
founded at physiological state.
Because of the persistence of the skin lesions, 
we proposed radiotherapy. The patient refused it. 
He agreed every 6 months close clinical follow-up. 
Over a seven years period, we noticed a progres-
sively disappearance of the skin lesions, leaving 
only a slight hyperpigmantation (Fig. 5).
Discussion
Classiﬁ  cation of lymphomas has always been a 
challenge because the nomenclature has changed 
many times over the past several decades to reﬂ  ect 
changes in our knowledge about the immunology 
and pathogenesis of these neoplasms. Although 
criteria for conﬁ  rming the primary nature of a 
cutaneous lymphoma have varied, a current 
working deﬁ  nition would be: a lymphoma which 
is determined to be confined to the skin after 
physical examination, chest/abdomen/pelvis imag-
ing studies, blood smear review, and bone marrow 
staging biopsies.
A major advance in our understanding of cuta-
neous B-cell lymphomas came from studies that 
began to separate primary from secondary forms. 
Since most series tended to group all cutaneous 
lymphomas and since PCBCL is a rare disorder, 
this seemingly basic difference tended to be over-
looked. Perhaps no other advance in the character-
ization of extranodal low-grade B-cell lymphomas 
has been as signiﬁ  cant in the past 20 years as the 
concept of extranodal marginal-zone B-cell MALT 
Figure 1. Multiple skin lesions on the neck, trunk and upper arms, consisting of inﬁ  ltrated deep red violaceus nodules measuring 1–1,5 cm.155
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lymphomas, ﬁ  rst introduced in 1983 (Isaacson and 
Wright, 1983; Isaacson 1999).
Burke et al. were among the ﬁ  rst to describe 
entities that are now considered characteristic of 
PCBCL (Burke et al. 1981; Santucci et al. 1991; 
Yang et al. 2000). The extension of MALT type 
lymphomas concept to the skin in the form of skin-
associated lymphoid tissue and so-called immuno-
cytomas of the skin helped deﬁ  ne a new type of 
PCBCL. Recognition of this type of lymphoma set 
the stage for modern classiﬁ  cations and deﬁ  nitions 
of PCBCL.
The typical immunophenotype is CD20+, CD5, 
CD10 with immunoglobulin (Ig) light chain restric-
tion. Monoclonal Ig gene rearrangement can be 
demonstrated by molecular genetic methods such 
as Southern blot or PCR. Recent studies conclude 
that known recurrent chromosomal abnormalities 
rarely occur in primary cutaneous MZLs and sug-
gest the possibility of a variety of initial oncogenic 
events leading to a common downstream pathway 
(de la Fouchardiere et al. 2006).
EMZL are thought to develop from reactive 
infiltrates that represent immune responses to 
external or autoantigens. Except for gastric EMZL, 
the antigenic triggers of EMZL development are 
mostly unknown, although a subset of cutaneous 
EMZL have been associated with Borrelia burg-
dorferi infections (Slader, 2001) and, recently with 
gastric Helicobacter pylori infection (Lefaki et al. 
2006). In our case none of these pathological agents 
was detected.
Like their counterparts in other extranodal sites, 
the behavior of EMZL is indolent (Cerroni et al. 
1997; de la Fouchardiere et al. 2005). The recent 
WHO/EORTC classiﬁ  cation (Burg et al. 2005) 
reviews the histological, pheotypical, and molecu-
lar genetic features and reminds that these ﬁ  ndings 
always have to be interpreted in the context of the 
clinical features and biological behaviour.
Figure 2. (a) Diffuse inﬁ  ltrate sparing the epidermis mainly composed of small lymphocytes. (b) The same Figure—higher magniﬁ  cation.
(a) (b)156
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Figure 3. Small CD20+ B cells.
Figure 4. CD10 antigen stain.157
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First-line therapy includes excision, local 
irradiation and chemotherapy. Recently were suc-
cessfully tried intralesional anti-CD20monoclonal 
antibody rituximab (Kyrtsonis et al. 2006) and 
IFNalpha2a (Cozzio et al. 2006).
The most PCBCL MALT type has an excellent 
prognosis. Cutaneous recurrence is common, but 
systemic dissemination and death from disease are 
uncommon. For patients with PCMZL who have 
multifocal lesions, chlorambucil therapy and 
radiotherapy are suitable therapeutic options. In 
case of cutaneous relapses, the beneﬁ  cial effects of 
treatment should carefully be weighed against the 
potential adverse effects (Hoefnagel et al. 2005).
We report a case of a young male with multiple 
lesions. The diagnosis was made based on WHO 
classiﬁ  cation. Without any therapeutical interven-
tion, the lesions disappeared over a seven years 
period. The known excellent prognosis and the 
indolent course of the disease in our patient, in 
association with close clinical follow-up succeed 
the cure in our case.
Conclusion
MZL, the predominant type of PCBCL, is having 
a good prognosis, although transformation can 
occur, needing a more aggressive treatment. 
The clinical evolution of our case suggests that in 
selected cases of histopathological and immuno-
logical proved MALT-type PCBCL, the “wait and 
see” strategy might be eligible, always with very 
close follow-up of the patient.
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